Investing
Cathie Wood's ARK Invest Buys Nearly 475,000 Shares of Signify Health
Published:
A couple ARK Invest exchange-traded funds run by ETF star Cathie Wood bought nearly 475,000 shares of Signify Health Inc. (NYSE: SGFY) on Tuesday, as the price of these funds were up more than 5% in Tuesday’s session. These funds had only turned negative recently in their performance over the past year.
[in-text-ad]
ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 160,234 shares of Signify Health, and ARK Innovation ETF (NYSEARCA: ARKK) added 313,766 shares. At Tuesday’s closing price, this would have valued thes purchases at roughly $7.2 million. This is only a small fraction of the total holdings. The Genomic Revolution fund is down 32% over the past 52 weeks, and the other is down nearly 16% in the same time.
Check out all the ARK Invest trades for Tuesday:
| Fund | Direction | Ticker | Name | Shares |
|---|---|---|---|---|
| ARKF | Buy | DSYSJ | DISCOVERY | 55,621 |
| ARKG | Buy | SGFY | SIGNIFY HEALTH | 160,234 |
| ARKG | Sell | TAK | TAKEDA PHARMACEUTICAL | 846,189 |
| ARKK | Buy | SGFY | SIGNIFY HEALTH | 313,766 |
| ARKK | Buy | TDOC | TELADOC HEALTH | 63,567 |
| ARKK | Sell | EDIT | EDITAS MEDICINE | 138,796 |
| ARKQ | Buy | BLDE | BLADE AIR MOBILITY | 11,926 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
